1e
19
1
49
2
2
18
1b
1d
18
2c
75
1d
2 29
1d
25
Leilei Xia, MD
88
75
Assistant Professor of Surgery at the Hospital of the University of Pennsylvania
28
70
3
5e
Active Physician, Pennsylvania Hospital, Philadelphia, PA
7b
Active Physician, Penn Presbyterian Medical Center, Philadelphia, PA
88
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
11
Department: Surgery
4
1
b
1d
46
Contact information
41
4
3
3
3
2
4
b
1f
41
Division of Urology
32 Hospital of the University of Pennsylvania
3d 3400 Spruce St., 3 W. PCAM
Philadelphia, PA 19104
26
32 Hospital of the University of Pennsylvania
3d 3400 Spruce St., 3 W. PCAM
Philadelphia, PA 19104
35
a3
12
13
Education:
21 7 MD c
3f Anhui Medical University, Hefei, China, 2012.
21 a M.Med 14 (Surgery) c
5a Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2015.
c
3
3
3
3
8d
Permanent link21 7 MD c
3f Anhui Medical University, Hefei, China, 2012.
21 a M.Med 14 (Surgery) c
5a Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2015.
c
2 29
21
1e
1d
24
2b
29
27
23
1bc Doshi C, Zahir M, Dadabhoy A, Xia L, Miranda G, Cai J, Daneshmand S: Evaluation of the potential impact of care fragmentation on survival outcomes in muscle invasive bladder cancer patients. Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 44, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
1c8 Davis R, Xia L, Miranda G, Cai J, Daneshmand S: Outcomes following neoadjuvant cisplatin-based chemotherapy and cystectomy for muscle invasive urothelial carcinoma with concomitant carcinoma in situ. Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 18-19, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
1ff Xia L, Dadabhoy A, Molina LS, Wood E, Lee Y, Miranda G, Cai J, Djaladat H, Schuckman A, Daneshmand S: Level of nodal metastasis in patients undergoing radical cystectomy and lymphadenectomy: Is there a role of extended lymphadenectomy in the post-S1011 era? Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 19, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
1a1 Doshi C, Dadabhoy A, Moghaddam FS, Wood E, Xia L, Daneshmand S: Assessing the diagnostic utility of cxbladder monitor as an alternative to surveillance cystoscopy. Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 94, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
20a Doshi C, Dadabhoy A, Ladi-Seyedian S, Xia L, Schuckman A, Daneshmand S: Alopecia as an uncommon side effect of single postoperative instillation of gemcitabine in patients with non-muscle invasive urothelial carcinoma of the bladder: A multi-institution experience. Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 93-94, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
19e Doshi C, Zahir M, Escobar D, Xia L, Daneshmand S: Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database. Journal of Clinical Oncology 43(Suppl 5), Feb. 2025 Notes: Presented at the 2025 American Society of Clinical Oncology ASCO Genitourinary Cancers Symposium, San Francisco, CA, Feb. 2025.
111 Doshi C, Zahir M, Dadabhoy A, Escobar D, Xia L, Daneshmand S: Serum tumor markers for muscle-invasive bladder cancer in clinical practice: A narrative review. Cancers (Basel) 17(5): 728, Feb. 21 2025.
19f Ku J, Doshi C, Dadabhoy A, Xia L, Daneshmand S: Clinicopathological variations between early and late recurrence in bladder cancer post-radical cystectomy. Journal of Clinical Oncology 43(Suppl 5), Feb. 2025 Notes: Presented at the 2025 American Society of Clinical Oncology ASCO Genitourinary Cancers Symposium, San Francisco, CA, Feb. 2025.
1de Zahir M, Doshi C, Escobar D, Xia L, Miranda G, Cai J, Schuckman AK, Djaladat H, Daneshmand S: Evaluating the survival benefits of adjuvant immunotherapy in muscle-invasive urothelial carcinoma: A real-world experience. Journal of Clinical Oncology 43(Suppl 5), Feb. 2025 Notes: Presented at the 2025 American Society of Clinical Oncology ASCO Genitourinary Cancers Symposium, San Francisco, CA, Feb. 2025.
2c
7
1d
1f
Selected Publications
16b Ribal MJ, Rosenberg J, Ajami T, Vilaseca A, Xia L, Sternschuss M, Schuckman AK: Advancing perioperative treatment options for localized muscle-invasive bladder cancer: A step forward. American Society of Clinical Oncology Educational Book 45(3): e472822, June 2025 Notes: Epub May 20, 2025.1bc Doshi C, Zahir M, Dadabhoy A, Xia L, Miranda G, Cai J, Daneshmand S: Evaluation of the potential impact of care fragmentation on survival outcomes in muscle invasive bladder cancer patients. Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 44, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
1c8 Davis R, Xia L, Miranda G, Cai J, Daneshmand S: Outcomes following neoadjuvant cisplatin-based chemotherapy and cystectomy for muscle invasive urothelial carcinoma with concomitant carcinoma in situ. Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 18-19, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
1ff Xia L, Dadabhoy A, Molina LS, Wood E, Lee Y, Miranda G, Cai J, Djaladat H, Schuckman A, Daneshmand S: Level of nodal metastasis in patients undergoing radical cystectomy and lymphadenectomy: Is there a role of extended lymphadenectomy in the post-S1011 era? Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 19, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
1a1 Doshi C, Dadabhoy A, Moghaddam FS, Wood E, Xia L, Daneshmand S: Assessing the diagnostic utility of cxbladder monitor as an alternative to surveillance cystoscopy. Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 94, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
20a Doshi C, Dadabhoy A, Ladi-Seyedian S, Xia L, Schuckman A, Daneshmand S: Alopecia as an uncommon side effect of single postoperative instillation of gemcitabine in patients with non-muscle invasive urothelial carcinoma of the bladder: A multi-institution experience. Urologic Oncology: Seminars & Original Investigations 43(3 Suppl): 93-94, Mar. 2025 Notes: Presented at the 25th Annual Meeting of the Society of Urology (SUO), Dallas, TX, Dec. 2024.
19e Doshi C, Zahir M, Escobar D, Xia L, Daneshmand S: Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database. Journal of Clinical Oncology 43(Suppl 5), Feb. 2025 Notes: Presented at the 2025 American Society of Clinical Oncology ASCO Genitourinary Cancers Symposium, San Francisco, CA, Feb. 2025.
111 Doshi C, Zahir M, Dadabhoy A, Escobar D, Xia L, Daneshmand S: Serum tumor markers for muscle-invasive bladder cancer in clinical practice: A narrative review. Cancers (Basel) 17(5): 728, Feb. 21 2025.
19f Ku J, Doshi C, Dadabhoy A, Xia L, Daneshmand S: Clinicopathological variations between early and late recurrence in bladder cancer post-radical cystectomy. Journal of Clinical Oncology 43(Suppl 5), Feb. 2025 Notes: Presented at the 2025 American Society of Clinical Oncology ASCO Genitourinary Cancers Symposium, San Francisco, CA, Feb. 2025.
1de Zahir M, Doshi C, Escobar D, Xia L, Miranda G, Cai J, Schuckman AK, Djaladat H, Daneshmand S: Evaluating the survival benefits of adjuvant immunotherapy in muscle-invasive urothelial carcinoma: A real-world experience. Journal of Clinical Oncology 43(Suppl 5), Feb. 2025 Notes: Presented at the 2025 American Society of Clinical Oncology ASCO Genitourinary Cancers Symposium, San Francisco, CA, Feb. 2025.
2c